Mammoth Private Capital LLC - Health & Tech Fund Series 2
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$10M
Investors
89
Min Invest
$50,000
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Mammoth Private Capital LLC - Health & Tech Fund Series 2 is a Delaware limited liability company that first filed a Form D on April 15, 2021 and most recently amended it on May 26, 2023, describing itself as a venture capital fund. The offering claims Rule 506(c), Section 3(c), Section 3(c)(7) and covers pooled investment fund interests. Mammoth Private Capital LLC - Health & Tech Fund Series 2 reported $10,371,000 sold from 89 investors of a $40,000,000 total offering as of the Form D filed May 26, 2023. The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $50,000. The Form D names The Securities Group dba Mammoth Research LLC (CRD 118148), associated with None; Ausdal Financial Partners Inc. (CRD 7995), associated with None as recipients of sales compensation soliciting in all states. The issuer's address of record is 9121 Illinois Road, Suite 51b, Fort Wayne, IN 46804.
Critical Disclosures
What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.
Reporting lapsed · Form D · last filing May 26, 2023
Offering declared to continue beyond a year; annual amendment 13+ months overdue An issuer that stops filing is the case the going-concern flag cannot catch: the report that would have carried it was never filed.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
dark
Fund family Part of the Mammoth Private Capital Health & Tech Fund family: 3 vehicles across 3 generations · full family and the filing behind each link in the terminal
Investor
- The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Adviser of Record (Form ADV)
CRD 314421 · lists this fund on Schedule D 7.B.(1) as a venture capital fund
From the adviser's Form ADV as loaded from the SEC bulk data through December 31, 2024, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
THOMAS MARTIN
Executive Officer · FORT WAYNE, IN
CHIEF EXECUTIVE OFFICER
SANJAY YADAV
Executive Officer · FORT WAYNE, IN
CHIEF INVESTMENT OFFICER
MATTHEW MCGIRT
Executive Officer · FORT WAYNE, IN
VICE PRESIDENT OF CLINICAL AND COMMERCIAL DEVELOPMENT
KIMBERLY MACKRILL
Executive Officer · FORT WAYNE, IN
CHIEF OPERATING OFFICER
JUD MACKRILL
Executive Officer · FORT WAYNE, IN
Chief Platform Officer
ERIN HECK
Executive Officer · FORT WAYNE, IN
CHIEF LEGAL OFFICER
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
The Securities Group dba Mammoth Research LLCCRD 118148 on BrokerCheck
Associated broker-dealer: None · Fort Wayne, IN · Soliciting in all states
Ausdal Financial Partners Inc.CRD 7995 on BrokerCheck
Associated broker-dealer: None · Davenport, IA · Soliciting in all states
Questions About Mammoth Private Capital LLC - Health & Tech Fund Series 2
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Mammoth Private Capital LLC - Health & Tech Fund Series 2?
Mammoth Private Capital LLC - Health & Tech Fund Series 2 is a Delaware limited liability company that filed a Form D with the SEC on May 26, 2023 as a venture capital fund. The filing claims Rule 506(c), Section 3(c), Section 3(c)(7) for an offering of pooled investment fund interests.
Is Mammoth Private Capital LLC - Health & Tech Fund Series 2 legit?
AltStreet does not rate legitimacy; it reports the public record. Mammoth Private Capital LLC - Health & Tech Fund Series 2 filed a Form D with the SEC on May 26, 2023 claiming Rule 506(c), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $10,371,000 sold to 89 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Mammoth Private Capital LLC - Health & Tech Fund Series 2 registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Mammoth Private Capital LLC - Health & Tech Fund Series 2 claimed Rule 506(c), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Mammoth Private Capital LLC - Health & Tech Fund Series 2 raised?
Mammoth Private Capital LLC - Health & Tech Fund Series 2 reported $10,371,000 sold from 89 investors of a $40,000,000 total offering as of the Form D filed May 26, 2023.
Who can invest in Mammoth Private Capital LLC - Health & Tech Fund Series 2?
The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $50,000.
What is the minimum investment in Mammoth Private Capital LLC - Health & Tech Fund Series 2?
The Form D lists $50,000 as the minimum investment accepted from any outside investor as of May 26, 2023. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Mammoth Private Capital LLC - Health & Tech Fund Series 2 and how are they paid?
The Form D names The Securities Group dba Mammoth Research LLC (CRD 118148), associated with None; Ausdal Financial Partners Inc. (CRD 7995), associated with None as recipients of sales compensation soliciting in all states.
Who is behind Mammoth Private Capital LLC - Health & Tech Fund Series 2?
The Form D lists 6 related persons: THOMAS MARTIN, executive officer (CHIEF EXECUTIVE OFFICER); SANJAY YADAV, executive officer (CHIEF INVESTMENT OFFICER); MATTHEW MCGIRT, executive officer (VICE PRESIDENT OF CLINICAL AND COMMERCIAL DEVELOPMENT); KIMBERLY MACKRILL, executive officer (CHIEF OPERATING OFFICER); JUD MACKRILL, executive officer (Chief Platform Officer); ERIN HECK, executive officer (CHIEF LEGAL OFFICER). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Mammoth Private Capital LLC - Health & Tech Fund Series 2 located?
The issuer's address on its SEC filings is 9121 Illinois Road, Suite 51b, Fort Wayne, IN 46804. Its phone number of record is 260-413-9184. It is organized under the laws of Delaware.
How long is the Mammoth Private Capital LLC - Health & Tech Fund Series 2 offering open?
The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 3 amendments are on record for this CIK.
How large is Mammoth Private Capital LLC - Health & Tech Fund Series 2?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.